High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update.
about
Focus on adoptive T cell transfer trials in melanomaAdoptive immunotherapy for cancer: building on successAdoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanomaSpecific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patientsAnalysis of the genome to personalize therapy for melanomaRobust tumor immunity to melanoma mediated by interleukin-9-producing T cellsTreatment of metastatic melanoma: an overviewChinese Guidelines on the Diagnosis and Treatment of Melanoma (2015 Edition)Updates in Therapy for Advanced MelanomaNatural Killer Cell-Based Therapies Targeting Cancer: Possible Strategies to Gain and Sustain Anti-Tumor ActivityPembrolizumab: First in Class for Treatment of Metastatic MelanomaUniverses collide: combining immunotherapy with targeted therapy for cancerCurrent vaccine trials in glioblastoma: a reviewOptimal management of metastatic melanoma: current strategies and future directionsAdoptive T-cell therapy using autologous tumor-infiltrating lymphocytes for metastatic melanoma: current status and future outlookIpilimumab: an anti-CTLA-4 antibody for metastatic melanomaRecent Advances in Immunotherapy in Metastatic NSCLCLong-term outcomes of helper peptide vaccination for metastatic melanoma.Function and Clinical Implications of Long Non-Coding RNAs in Melanoma.Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic MelanomaA phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanomaResults of systemic treatment of cutaneous melanoma in inoperable stage III and IVDurable responses and reversible toxicity of high-dose interleukin-2 treatment of melanoma and renal cancer in a Community Hospital Biotherapy Program.Melanoma in pediatric, adolescent, and young adult patients.The soy-derived peptide Lunasin inhibits invasive potential of melanoma initiating cellsExpansion and characterization of human melanoma tumor-infiltrating lymphocytes (TILs)Correlation of somatic mutations and clinical outcome in melanoma patients treated with Carboplatin, Paclitaxel, and sorafenibMelanoma patients in a phase I clinic: molecular aberrations, targeted therapy and outcomes.Understanding the biology of melanoma and therapeutic implicationsThe Role of B-RAF Mutations in Melanoma and the Induction of EMT via Dysregulation of the NF-κB/Snail/RKIP/PTEN CircuitNatural killer cells for cancer immunotherapy: pluripotent stem cells-derived NK cells as an immunotherapeutic perspectiveA phase I trial of bortezomib and interferon-α-2b in metastatic melanoma.Sensitive detection of pathway perturbations in cancersRadiotherapy as an immunological booster in patients with metastatic melanoma or renal cell carcinoma treated with high-dose Interleukin-2: evaluation of biomarkers of immunologic and therapeutic response.Efficacy of adoptive cell transfer of tumor-infiltrating lymphocytes after lymphopenia induction for metastatic melanoma.Phase II trial of sagopilone, a novel epothilone analog in metastatic melanoma.Releasing the brake on the immune system: ipilimumab in melanoma and other tumorsLong-term survival in advanced melanoma patients using repeated therapies: successive immunomodulation improving the odds?Immunotherapy coming of age: what will it take to make it standard of care for glioblastoma?Characterization of human γδ T lymphocytes infiltrating primary malignant melanomas.
P2860
Q21328679-8696BF8C-DF9F-499B-B913-2DBE09ADD24CQ24546258-A6DE5BD5-B1C8-4ECA-8578-F232FA9C8987Q24548019-2BBFA9A2-49D6-438E-BC12-ADBB31DA0140Q24598792-E74B0DB7-FF03-44C0-897C-217331CEC542Q24601008-CD2D05A2-E6DD-4ED1-AFEA-E265F6774A28Q24601213-D53410EB-D452-4B45-8337-6174A93B8B7FQ24642384-D1791C87-0716-4D53-A47E-EDC439B13AEAQ26770492-FBFC71F6-2532-4B68-9D4C-6EDCCDDB67BAQ26771119-D605013A-4B1E-49D4-B9F2-9E0C2F74937CQ26773135-3AC35474-0394-4D0A-A29C-04CB1F36700DQ26777886-CBE00B29-68B6-41E1-AAFC-98592FB03912Q26825316-FDB6B848-DFB8-49AF-A81B-559D1A419B4AQ26828965-35D1559C-A3EA-43DB-83F5-42F60BFD3DF6Q26997338-F5E2AA0C-DD92-4FBB-9873-0380637133BFQ27004178-3CCD51DB-A34F-4B0A-ADC6-ECA4158ED2CDQ27005902-C02D1374-7A88-4C59-B244-70A93AE7B288Q28069323-F9FFC200-3610-44B0-91B4-FFC0F4BDECA3Q30278874-251D2F0C-3EAC-48D6-A5E6-D6B74BE8B7C0Q30313298-A7430CE5-449B-4C07-85FC-2037B9478B0FQ30890582-170DC56D-8183-4863-B9DE-48FBEF747C98Q33342339-A7B9623C-324A-487E-9473-B689F3838100Q33408564-138BED71-A8B1-45D5-90C3-A209549D816BQ33415481-4C85F99B-1E91-4FE4-A539-99C929B9A084Q33554622-35CF3637-7172-4B94-8015-029D251BA259Q33648931-7A398619-ADC7-4949-9BF5-02F2AAE9FDD2Q33750205-088DDADA-D8DF-4A58-8468-455120931635Q33758211-A52DC99F-51D5-475F-919D-ADBC1BF40A25Q33845387-BEBD26A9-77EE-47C6-8938-43002EDEB282Q33978378-BF801C5E-6AA9-4933-BBC4-C124CF9A4BD4Q34106285-60DF1A07-0C13-4E52-B4B3-772A63A6DD74Q34180695-388DA1E9-71E6-4A6A-A5EE-DFBF4C0B4A10Q34241208-72A9FB51-F3F4-4712-A8E2-6FF38F128339Q34247915-C06413B9-8636-4264-92E5-322EEF88EC41Q34278609-6CCC4744-99B1-49E4-87F9-ED3B64EFA475Q34300883-422851DA-3C3B-40BA-811B-395FA1132463Q34343995-D1A6444A-278D-4D9A-A157-4E1E57798498Q34447732-AD5A4493-7038-4B90-848C-BE2E3DBE9D7EQ34477227-238ABE90-F49F-4289-AED4-EB4C9D57FA4AQ34480557-9B026720-B199-48DB-923C-B9E5FEB91B2AQ34493921-1AD9B857-C666-42D0-82B8-0CBCE3571B2C
P2860
High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update.
description
2000 nî lūn-bûn
@nan
2000 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
High-dose recombinant interleu ...... ma: long-term survival update.
@ast
High-dose recombinant interleu ...... ma: long-term survival update.
@en
High-dose recombinant interleu ...... ma: long-term survival update.
@nl
type
label
High-dose recombinant interleu ...... ma: long-term survival update.
@ast
High-dose recombinant interleu ...... ma: long-term survival update.
@en
High-dose recombinant interleu ...... ma: long-term survival update.
@nl
prefLabel
High-dose recombinant interleu ...... ma: long-term survival update.
@ast
High-dose recombinant interleu ...... ma: long-term survival update.
@en
High-dose recombinant interleu ...... ma: long-term survival update.
@nl
P2093
P1476
High-dose recombinant interleu ...... ma: long-term survival update.
@en
P2093
P478
P577
2000-02-01T00:00:00Z